Vaxcyte (PCVX)
(Delayed Data from NSDQ)
$79.35 USD
+1.21 (1.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $79.24 -0.11 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Vaxcyte, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 468 | 232 | 104 | 90 | 54 |
Income After Depreciation & Amortization | -468 | -232 | -104 | -90 | -54 |
Non-Operating Income | 66 | 9 | 4 | 0 | 4 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -402 | -223 | -100 | -89 | -50 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -402 | -223 | -100 | -89 | -50 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -402 | -223 | -100 | -89 | -50 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -493 | -224 | -99 | -88 | -53 |
Depreciation & Amortization (Cash Flow) | -25 | 8 | 5 | 1 | 1 |
Income After Depreciation & Amortization | -468 | -232 | -104 | -90 | -54 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 97.16 | 64.88 | 51.92 | 29.55 | NA |
Diluted EPS Before Non-Recurring Items | -4.14 | -3.09 | -1.93 | -3.02 | NA |
Diluted Net EPS (GAAP) | -4.14 | -3.44 | -1.93 | -3.02 | -13.25 |
Fiscal Year end for Vaxcyte, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 152.98 | 114.48 | 121.68 | 113.03 | 87.15 |
Income After SG&A, R&D, and Dept/Amort Expenses | -152.98 | -114.48 | -121.68 | -113.03 | -87.15 |
Non-Operating Income | 24.28 | 19.45 | 15.88 | 20.36 | 18.81 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -128.70 | -95.02 | -180.80 | -92.66 | -68.34 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -128.70 | -95.02 | -180.80 | -92.66 | -68.34 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -128.70 | -95.02 | -180.80 | -92.66 | -68.34 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 117.26 | 111.69 | 97.16 | 101.67 | 98.06 |
Diluted EPS Before Non-Recurring Items | -1.10 | -0.85 | -1.82 | -0.91 | -0.70 |
Diluted Net EPS (GAAP) | -1.10 | -0.85 | -1.83 | -0.91 | -0.70 |